Compare AU
Compare CRYP vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Crypto Innovators ETF (CRYP) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CRYP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 748 | 80 |
Median incremental investment | $787.21 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,127.91 | $1,279.69 |
Average age group | > 35 | > 35 |
Key Summary
CRYP | CURE | |
|---|---|---|
Strategy | CRYP.AX was created on 2021-11-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. CRYP.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to global companies at the forefront of the crypto economy. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | JPY - JAPANESE YEN (0 %) MICROSTRATEGY INC (10.54 %) GALAXY DIGITAL HOLDINGS LTD (10.01 %) | Neurocrine Biosciences Inc (2.72 %) Natera Inc (2.49 %) Gilead Sciences Inc (2.45 %) |
Top 3 industries | Other (49.17 %) Information Technology (25.67 %) Financials (23.51 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (81.18 %) Germany (4.60 %) Australia (3.91 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.67 % | 0.45 % |
Key Summary
CRYP | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Bitwise Crypto Innovator Index - aud - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.67 % | 0.45 % |
Price | $7.97 | $48.29 |
Size | $208.929 million | $34.226 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | - % | 4.24 % |
Market | ASX | ASX |
First listed date | 03/11/2021 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CRYP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 748 | 80 |
Median incremental investment | $787.21 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,127.91 | $1,279.69 |
Average age group | > 35 | > 35 |
Pros and Cons
CRYP | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CRYP | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |